Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the ...
Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars ...
Asianet Newsable on MSN
Common Nutrient Zeaxanthin Could Strengthen T Cells Against Cancer
Zeaxanthin, a nutrient found in spinach and peppers, boosts T-cell cancer-fighting power. New research shows it could enhance ...
Hosted on MSN
Engineered T-cells that express both CARs and TCRs can better distinguish between cancerous and healthy tissues
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer treatments. This study, published in Cell, demonstrates that engineering T-cells to ...
News-Medical.Net on MSN
New T cell therapy targets CTNNB1 cancer mutation with promising results in animal studies
Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the ...
Planegg/Martinsried, 22 June 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid ...
Vietnam Investment Review on MSN
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and ...
Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that are utilized in multiple therapeutic modalities, such as T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback